I am on the same page as you, Jonzobot. 

The market is slowly going to understand the huge significance of our Breakthrough Therapy designation.  It radically changes the views of the medical profession...about Apabetalone, RVX, Epigenetics for CVD/CKD.  As Cityslicker99 noted so beautifully, RVX is no longer a small biotech company out of Calgary with unproven science.  We are in serious league now. 

In one stroke, not only has the time to market for our molecule been cut by at least 2 years, it has also made it a near certainty that it will be approved (assuming the only issue was under powering of Phase 3).  Plus, other indications...CKD obviously, but Dementia and who knows what more is on the way.  What else can a buyer of RVX want?

The next level is $1.40, where the 100 day MA comes in, followed by $2.30 for the 200 day MA.  After that, we are in a different outcome situation.  

Hang on all...it will keep getting better!

Iconoclast